Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

KALA BIO Yönetim

Yönetim kriter kontrolleri 2/4

KALA BIO's CEO'su Mark Iwicki, Sep2015 tarihinde atandı, in görev süresi 9.08 yıldır. in toplam yıllık tazminatı $ 8.34M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.5% maaş ve 91.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.57% ine doğrudan sahiptir ve bu hisseler $ 412.97K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.4 yıl ve 7.1 yıldır.

Anahtar bilgiler

Mark Iwicki

İcra Kurulu Başkanı

US$8.3m

Toplam tazminat

CEO maaş yüzdesi	8.5%
CEO görev süresi	9.1yrs
CEO sahipliği	1.6%
Yönetim ortalama görev süresi	6.4yrs
Yönetim Kurulu ortalama görev süresi	7.1yrs

Son yönetim güncellemeleri

Recent updates

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Aug 10

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Jul 07

CEO Tazminat Analizi

Mark Iwicki'un ücretlendirmesi KALA BIO'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$39m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$8m	US$709k	-US$42m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$2m	US$682k	-US$45m
Sep 30 2022	n/a	n/a	-US$80m
Jun 30 2022	n/a	n/a	-US$137m
Mar 31 2022	n/a	n/a	-US$145m
Dec 31 2021	US$3m	US$644k	-US$143m
Sep 30 2021	n/a	n/a	-US$126m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$5m	US$586k	-US$104m
Sep 30 2020	n/a	n/a	-US$95m
Jun 30 2020	n/a	n/a	-US$90m
Mar 31 2020	n/a	n/a	-US$91m
Dec 31 2019	US$3m	US$564k	-US$94m
Sep 30 2019	n/a	n/a	-US$98m
Jun 30 2019	n/a	n/a	-US$90m
Mar 31 2019	n/a	n/a	-US$81m
Dec 31 2018	US$3m	US$535k	-US$67m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$47m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	US$2m	US$501k	-US$42m

Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 8.34M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Mark şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Mark Iwicki (58 yo)

9.1yrs

Görev süresi

US$8,342,714

Tazminat

Mr. Mark T. Iwicki has been Director at Q32 Bio Inc since March 2023. Mr. Iwicki previously served as the Chairman of Legacy Q32’s board of directors since 2020. He had been Chairman of Aerovate Therapeuti...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Iwicki	Chairman & CEO	9.1yrs	US$8.34m	1.57% $ 397.0k
Todd Bazemore	President & COO	6.9yrs	US$2.94m	0.49% $ 122.7k
R. Brazzell	Head of R&D and Chief Medical Officer	11.7yrs	US$2.92m	0.54% $ 135.3k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	Veri yok	Veri yok
Mary Reumuth	CFO & Treasurer	10.7yrs	Veri yok	0.35% $ 88.0k
Jill Steier	Executive Director of Investor Relations & Corporate Communications	3.3yrs	Veri yok	Veri yok
Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	7.3yrs	Veri yok	Veri yok
Darius Kharabi	Chief Business Officer	2.9yrs	Veri yok	0.48% $ 121.4k
Francis Mah	Chief Medical Advisor	1.6yrs	Veri yok	Veri yok
Josiah Craver	Senior VP & Corporate Controller	2.5yrs	Veri yok	Veri yok
Carl Rennie	Executive Director of Account Management	6.4yrs	Veri yok	Veri yok
Patrick Bedell	Executive Director of Trade & Alternate Channels	6.4yrs	Veri yok	Veri yok

6.4yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: KALA 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Iwicki	Chairman & CEO	9.5yrs	US$8.34m	1.57% $ 397.0k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	Veri yok	Veri yok
Jonathan Silverstein	Board Observer	8.5yrs	Veri yok	Veri yok
Gregory Perry	Independent Director	6.7yrs	US$302.01k	0.051% $ 13.0k
Peter Hutt	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Andrew Koven	Lead Independent Director	7.1yrs	US$402.36k	0.066% $ 16.8k
Mark Blumenkranz	Independent Director	2.9yrs	US$234.09k	0.17% $ 42.5k
Ronald Krall	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Bennett Shapiro	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Colin Gardner	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Charles Myers	Independent Director	3yrs	US$236.94k	0.029% $ 7.2k
Howard Rosen	Independent Director & Member of Advisory Board	10.8yrs	US$392.20k	0.065% $ 16.5k

7.1yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KALA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.1 yıldır).

KALA BIO Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Recent updates

New major risk - Share price stability

Price target decreased by 15% to US$16.50

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Price target decreased to US$42.00

Price target decreased to US$90.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Kala Pharmaceuticals to execute reverse stock split

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Consensus revenue estimates fall by 27%

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$4.55

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

Staying Patient With Kala Pharmaceuticals

Consensus revenue estimates fall to US$19.9m

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Price target decreased to US$16.50

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi